Kentucky Retirement Systems Raises Stock Holdings in CVS Health Corporation $CVS

Kentucky Retirement Systems raised its position in shares of CVS Health Corporation (NYSE:CVS) by 25.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 98,269 shares of the pharmacy operator’s stock after buying an additional 19,633 shares during the period. Kentucky Retirement Systems’ holdings in CVS Health were worth $7,033,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares in the last quarter. Swiss RE Ltd. acquired a new position in CVS Health during the fourth quarter valued at $26,000. Sankala Group LLC purchased a new stake in CVS Health in the fourth quarter valued at $28,000. Global Trust Asset Management LLC grew its position in CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. purchased a new position in shares of CVS Health during the 4th quarter valued at about $28,000. 80.66% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent research reports. Wells Fargo & Company upped their target price on CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. UBS Group lifted their price target on CVS Health from $115.00 to $122.00 and gave the company a “buy” rating in a research report on Friday, July 24th. TD Cowen boosted their price target on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Robert W. Baird raised their price objective on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Finally, Mizuho lifted their target price on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Twenty-one analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $105.67.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts expect CVS Health’s upcoming earnings to show continued growth, with favorable earnings and revenue trends cited as potential catalysts for a beat. The outlook is supported by resilient healthcare demand and the company’s latest reported quarter, when CVS exceeded consensus EPS and revenue estimates. CVS Health Earnings Expected to Grow
• Positive Sentiment: CVS Pharmacy has begun offering common prescription medications for dogs and cats at approximately 9,000 locations, expanding its retail healthcare offering and creating a potential incremental source of pharmacy traffic and revenue. Pet Medications Now Available at CVS Pharmacy
• Positive Sentiment: Health100, a CVS subsidiary, earned DirectTrust accreditation under the CARIN Code of Conduct for consumer-facing applications. The recognition may strengthen confidence in the Health100 app’s data privacy and security, although the near-term financial effect is likely limited. Health100 Earns Industry Accreditation
• Neutral Sentiment: X and the World Federation of Advertisers settled litigation related to an alleged advertiser boycott. CVS was previously identified among companies accused by X, but the settlement appears unlikely to have a material direct effect on CVS’s operations or earnings. X and WFA Settle Litigation
• Negative Sentiment: Potentially ending Medicare Part D subsidies for 2027 is the most significant near-term concern. Investors may be reassessing CVS’s Medicare exposure, even as the company continues to benefit from expectations for earnings growth and recent operating momentum. Potential Medicare Part D Subsidy Changes

CVS Health Trading Down 3.0%

Shares of CVS stock opened at $106.02 on Thursday. CVS Health Corporation has a fifty-two week low of $61.00 and a fifty-two week high of $110.68. The firm has a market capitalization of $135.27 billion, a P/E ratio of 46.70, a PEG ratio of 1.07 and a beta of 0.61. The stock’s fifty day moving average is $100.99 and its two-hundred day moving average is $86.74. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts expect that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be given a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s dividend payout ratio is 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.